LZTS1

Across TCGA pan-cancer cohorts, LZTS1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LZTS1 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher LZTS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LZTS1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SCLC, KIRC, and KICH are the cancer types where LZTS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	48	view →
KIRC	OS	Median	All	0.062	0.874	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LIHC	DFS	Median	All	0.105	0.555	.004	6	view →
BLCA	DFS	Median	All	1.000	0.330	.048	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	All	0.226	0.757	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LZTS1–SCLC (OS)

Open the SCLC breakdown →